JP2009504142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504142A5 JP2009504142A5 JP2008525399A JP2008525399A JP2009504142A5 JP 2009504142 A5 JP2009504142 A5 JP 2009504142A5 JP 2008525399 A JP2008525399 A JP 2008525399A JP 2008525399 A JP2008525399 A JP 2008525399A JP 2009504142 A5 JP2009504142 A5 JP 2009504142A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- growth factor
- marker protein
- encoded
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003550 marker Substances 0.000 claims 51
- 108090000623 proteins and genes Proteins 0.000 claims 48
- 102000004169 proteins and genes Human genes 0.000 claims 31
- 238000000034 method Methods 0.000 claims 18
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 8
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 8
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 101800003838 Epidermal growth factor Proteins 0.000 claims 6
- 239000004010 HER dimerization inhibitor Substances 0.000 claims 6
- 229940116977 epidermal growth factor Drugs 0.000 claims 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 4
- -1 -Amphiregulin Proteins 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- 108700020796 Oncogene Proteins 0.000 claims 3
- 102000043276 Oncogene Human genes 0.000 claims 3
- 102000007299 Amphiregulin Human genes 0.000 claims 2
- 108010033760 Amphiregulin Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000003365 immunocytochemistry Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017663 | 2005-08-12 | ||
| PCT/EP2006/004950 WO2007019899A2 (en) | 2005-08-12 | 2006-05-24 | Method for predicting the response to a treatment with a her dimerization inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504142A JP2009504142A (ja) | 2009-02-05 |
| JP2009504142A5 true JP2009504142A5 (enExample) | 2009-05-28 |
Family
ID=35511140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525399A Pending JP2009504142A (ja) | 2005-08-12 | 2006-05-24 | 治療に対する応答を予測するための方法 |
Country Status (32)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO2001089566A1 (en) | 2000-05-19 | 2001-11-29 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| UA90480C2 (uk) * | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| EP3698807A1 (en) * | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
| RS53128B (sr) * | 2005-02-23 | 2014-06-30 | Genentech Inc. | Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| WO2007025044A2 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| JP5433189B2 (ja) * | 2007-09-28 | 2014-03-05 | 承一 尾崎 | Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法 |
| WO2009086197A1 (en) * | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
| NZ586544A (en) * | 2007-12-26 | 2012-07-27 | Vaccinex Inc | Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US9879267B2 (en) * | 2008-03-14 | 2018-01-30 | Genentech, Inc. | Genetic variations associated with drug resistance |
| NZ589143A (en) * | 2008-05-14 | 2012-02-24 | Genomic Health Inc | Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| EP2438442B1 (en) | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| US20100233732A1 (en) * | 2009-01-15 | 2010-09-16 | Laboratory Corporation Of America Holdings | Methods of Determining Patient Response By Measurement of HER-2 Expression |
| BRPI1007321A2 (en) | 2009-01-15 | 2018-07-10 | Laboratory Corporation Of America Holdings | methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody. |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2011132182A1 (en) * | 2010-04-18 | 2011-10-27 | Yeda Research And Development Co. Ltd. | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| WO2012094636A2 (en) * | 2011-01-07 | 2012-07-12 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| EP2764364B1 (en) * | 2011-10-06 | 2021-08-18 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
| HUE044352T2 (hu) | 2011-10-14 | 2019-10-28 | Hoffmann La Roche | Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére |
| CN104349773A (zh) | 2012-01-06 | 2015-02-11 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
| BR112014016808B1 (pt) | 2012-01-06 | 2022-01-11 | Anji Pharma (Us) Llc | Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose |
| MY173295A (en) | 2013-04-16 | 2020-01-14 | Genentech Inc | Pertuzumab variants and evaluation thereof |
| CA2919477A1 (en) * | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
| EP2876442A1 (en) | 2013-11-22 | 2015-05-27 | Institut de Cancérologie de l'Ouest | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer |
| BR112016024789A2 (pt) | 2014-04-25 | 2017-10-24 | Genentech Inc | métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe |
| JP2017528430A (ja) | 2014-07-17 | 2017-09-28 | ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． | 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定 |
| JP6822980B2 (ja) | 2015-05-30 | 2021-01-27 | ジェネンテック， インコーポレイテッド | Ｈｅｒ２陽性転移性乳癌の治療方法 |
| CA2992925A1 (en) * | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN105403704A (zh) * | 2015-12-31 | 2016-03-16 | 苏州市博纳泰科生物技术有限公司 | Her-2的荧光免疫层析检测方法及试剂盒 |
| EP3534948A1 (en) | 2016-11-04 | 2019-09-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック， インコーポレイテッド | 進行したｈｅｒ２発現がんの治療 |
| DK3570884T3 (da) | 2017-01-17 | 2020-11-30 | Genentech Inc | Subkutane HER2-antistofformuleringer |
| HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| MY199134A (en) | 2018-05-25 | 2023-10-17 | Bioneer Corp | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis related diseases and respiratory diseases, comprising same |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| EP4568994A1 (en) * | 2022-08-09 | 2025-06-18 | Heligenics, Inc. | Method for evaluating clinical relevance of genetic variance |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6759217B2 (en) * | 1996-03-26 | 2004-07-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| CN101412758A (zh) | 1996-10-18 | 2009-04-22 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7081340B2 (en) * | 2002-03-13 | 2006-07-25 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| HUP0600340A3 (en) * | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| WO2004053497A2 (en) * | 2002-12-11 | 2004-06-24 | Ventana Medical Systems, Inc. | Method for predicting the response to her2-directed therapy |
| WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| BRPI0408928A (pt) | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
| WO2005049829A1 (en) | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Process |
| WO2005011607A2 (en) | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| WO2005047534A2 (en) | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Methods and compositions for the response prediction of malig-nant neoplasia to treatment |
| TWM256978U (en) * | 2004-04-02 | 2005-02-11 | Nventec Appliances Corp | Electronic device |
| CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| RU2300111C2 (ru) * | 2005-06-15 | 2007-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ прогнозирования течения заболевания раком молочной железы |
-
2006
- 2006-05-19 US US11/438,033 patent/US7700299B2/en not_active Expired - Fee Related
- 2006-05-23 TW TW095118273A patent/TW200741010A/zh unknown
- 2006-05-24 EP EP10156100A patent/EP2196547B1/en not_active Expired - Lifetime
- 2006-05-24 RS RS20110132A patent/RS51859B/sr unknown
- 2006-05-24 AU AU2006281746A patent/AU2006281746B2/en not_active Ceased
- 2006-05-24 DK DK06743052.0T patent/DK1915460T3/da active
- 2006-05-24 NZ NZ565270A patent/NZ565270A/en not_active IP Right Cessation
- 2006-05-24 ES ES06743052T patent/ES2356066T3/es not_active Expired - Lifetime
- 2006-05-24 SI SI200630946T patent/SI1915460T1/sl unknown
- 2006-05-24 CA CA002616913A patent/CA2616913A1/en not_active Abandoned
- 2006-05-24 AT AT10156100T patent/ATE539171T1/de active
- 2006-05-24 WO PCT/EP2006/004950 patent/WO2007019899A2/en not_active Ceased
- 2006-05-24 CN CN200910204668A patent/CN101705287A/zh active Pending
- 2006-05-24 BR BRPI0615001-2A patent/BRPI0615001A2/pt not_active IP Right Cessation
- 2006-05-24 KR KR1020117011685A patent/KR20110074921A/ko not_active Ceased
- 2006-05-24 CN CNA2006800289513A patent/CN101405405A/zh not_active Withdrawn
- 2006-05-24 PT PT06743052T patent/PT1915460E/pt unknown
- 2006-05-24 KR KR1020087003440A patent/KR20080034922A/ko not_active Ceased
- 2006-05-24 AR ARP060102149A patent/AR057323A1/es not_active Application Discontinuation
- 2006-05-24 EP EP06743052A patent/EP1915460B1/en not_active Expired - Lifetime
- 2006-05-24 MX MX2008001926A patent/MX2008001926A/es active IP Right Grant
- 2006-05-24 UA UAA200803055A patent/UA93989C2/ru unknown
- 2006-05-24 DE DE602006019265T patent/DE602006019265D1/de not_active Expired - Lifetime
- 2006-05-24 HR HR20110171T patent/HRP20110171T1/hr unknown
- 2006-05-24 JP JP2008525399A patent/JP2009504142A/ja active Pending
- 2006-05-24 AT AT06743052T patent/ATE493514T1/de active
- 2006-05-24 PL PL06743052T patent/PL1915460T3/pl unknown
- 2006-05-24 RU RU2008108907/10A patent/RU2408735C2/ru not_active IP Right Cessation
-
2008
- 2008-01-21 IL IL188923A patent/IL188923A0/en unknown
- 2008-01-21 NO NO20080371A patent/NO20080371L/no not_active Application Discontinuation
- 2008-01-24 CR CR9686A patent/CR9686A/es not_active Application Discontinuation
- 2008-02-06 MA MA30621A patent/MA31549B1/fr unknown
- 2008-02-11 EC EC2008008171A patent/ECSP088171A/es unknown
-
2009
- 2009-11-24 US US12/624,443 patent/US20100112603A1/en not_active Abandoned
-
2010
- 2010-04-19 RU RU2010115252/10A patent/RU2010115252A/ru not_active Application Discontinuation
- 2010-07-06 CL CL2010000720A patent/CL2010000720A1/es unknown
-
2011
- 2011-03-15 CY CY20111100286T patent/CY1111612T1/el unknown
- 2011-04-11 ZA ZA2011/02688A patent/ZA201102688B/en unknown
- 2011-05-19 AU AU2011202339A patent/AU2011202339A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2408735C2 (ru) | Способ предсказания ответа на лечение | |
| JP2009521215A5 (enExample) | ||
| CN107076749B (zh) | 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志 | |
| KR20130091750A (ko) | 유방암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커 | |
| CN103898205B (zh) | 半胱氨酸蛋白酶抑制剂sn的应用 | |
| KR20130091746A (ko) | 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커 | |
| EP1996940A4 (en) | DETECTION OF CANCER DUE TO INCREASED BCL-2 CONCENTRATIONS | |
| MX2011013578A (es) | Biomarcadores y metodos para determinar la eficacia de anticuerpos anti-receptor del factor de crecimiento epidermal (anti-egfr) en terapia de cancer. | |
| NO20076656L (no) | Forbedrede immunoassay metoder | |
| RU2011150279A (ru) | Фосфодиэстераза 4d7 как маркер рака предстательной железы | |
| US20210310080A1 (en) | Composition for diagnosing cancer using potassium channel proteins | |
| Miyoshi et al. | Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma | |
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| JP2007533985A5 (enExample) | ||
| RU2011150291A (ru) | Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы | |
| NZ593392A (en) | Biomarker for detecting bladder cancer | |
| JP5702944B2 (ja) | バイオマーカー | |
| WO2016194348A1 (en) | Biomarkers for a combination therapy comprising lenvatinib and everolimus | |
| KR20240151659A (ko) | 폐암 치료의 반응 및 효능 평가와 예후 예측용 바이오 마커 | |
| KR20160050727A (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| WO2020071457A1 (en) | Biomarkers for a combination therapy comprising lenvatinib and everolimus | |
| JP2009517381A5 (enExample) | ||
| KR102136747B1 (ko) | 장형 위암의 예후 진단 마커 | |
| KR20220148615A (ko) | 위암의 예후 예측 방법 | |
| WO2007127002A3 (en) | Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors |